About 2 Trademarks found for “*QAY”
Filters
Also try searching for:
QAY*
| Mark | Details | Status | Class/Description | |
|---|---|---|---|---|
 | OSQAY Theramex HQ UK Limited 2432008 1 Mar 2024 | Registered: Registered/protected | Pharmaceutical preparations and substances for the treatment of osteop... Class 005 Class 005 Pharmaceutical Products Pharmaceutical preparations and substances for the treatment of osteoporosis; pharmaceutical preparations and substances for the alleviation of osteoporosis-related symptoms; pharmaceutical preparations and substances for the treatment of cartilage disorders; pharmaceutical preparations and substances for the treatment of bone disorders; pharmaceutical preparations and substances for the treatment of bone loss; pharmaceutical preparations and substances for the alleviation of bone-loss related symptoms; pharmaceutical preparations and substances for use in endocrinology; pharmaceutical preparations and substances for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures; pharmaceutical preparations and substances for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures; pharmaceutical preparations and substances for the treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture; pharmaceutical preparations for the treatment of menopause; pharmaceutical preparations and substances for the alleviation of menopause-related symptoms; pharmaceutical preparations and substances for use in relation to women’s health; pharmaceutical preparations and substances for use in rheumatology; pharmaceutical preparations and substances for the treatment of arthritis; pharmaceutical preparations and substances for the treatment of rheumatoid arthritis; pharmaceutical preparations and substances for the treatment of juvenile idiopathic polyarthritis; pharmaceutical preparations and substances for the treatment of active systemic juvenile idiopathic arthritis; pharmaceutical preparations and substances for use in endocrinology; pharmaceutical preparations and substances for use in the treatment of respiratory conditions; pharmaceutical preparations and substances for use in the treatment of coronavirus disease;; pharmaceutical preparations and substances for use in the treatment of cytokine release syndrome; all the above being for human use. | |
| OSQAY Theramex HQ UK Limited 2430180 23 Feb 2024 | Accepted: In opposition period | Pharmaceutical preparations and substances for the treatment of osteop... Class 005 Class 005 Pharmaceutical Products Pharmaceutical preparations and substances for the treatment of osteoporosis; pharmaceutical preparations and substances for the alleviation of osteoporosis-related symptoms; pharmaceutical preparations and substances for the treatment of cartilage disorders; pharmaceutical preparations and substances for the treatment of bone disorders; pharmaceutical preparations and substances for the treatment of bone loss; pharmaceutical preparations and substances for the alleviation of bone-loss related symptoms; pharmaceutical preparations and substances for use in endocrinology; pharmaceutical preparations and substances for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures; pharmaceutical preparations and substances for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures; pharmaceutical preparations and substances for the treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture; pharmaceutical preparations for the treatment of menopause; pharmaceutical preparations and substances for the alleviation of menopause-related symptoms; pharmaceutical preparations and substances for use in relation to women’s health; pharmaceutical preparations and substances for use in rheumatology; pharmaceutical preparations and substances for the treatment of arthritis; pharmaceutical preparations and substances for the treatment of rheumatoid arthritis; pharmaceutical preparations and substances for the treatment of juvenile idiopathic polyarthritis; pharmaceutical preparations and substances for the treatment of active systemic juvenile idiopathic arthritis; pharmaceutical preparations and substances for use in endocrinology; pharmaceutical preparations and substances for use in the treatment of respiratory conditions; pharmaceutical preparations and substances for use in the treatment of coronavirus disease;; pharmaceutical preparations and substances for use in the treatment of cytokine release syndrome; all the above being for human use. |
Theramex HQ UK Limited
2432008 · 1 Mar 2024
005
Class 005
Pharmaceutical Products
Pharmaceutical preparations and substances for the treatment of osteoporosis; pharmaceutical preparations and substances for the alleviation of osteoporosis-related symptoms; pharmaceutical preparations and substances for the treatment of cartilage disorders; pharmaceutical preparations and substances for the treatment of bone disorders; pharmaceutical preparations and substances for the treatment of bone loss; pharmaceutical preparations and substances for the alleviation of bone-loss related symptoms; pharmaceutical preparations and substances for use in endocrinology; pharmaceutical preparations and substances for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures; pharmaceutical preparations and substances for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures; pharmaceutical preparations and substances for the treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture; pharmaceutical preparations for the treatment of menopause; pharmaceutical preparations and substances for the alleviation of menopause-related symptoms; pharmaceutical preparations and substances for use in relation to women’s health; pharmaceutical preparations and substances for use in rheumatology; pharmaceutical preparations and substances for the treatment of arthritis; pharmaceutical preparations and substances for the treatment of rheumatoid arthritis; pharmaceutical preparations and substances for the treatment of juvenile idiopathic polyarthritis; pharmaceutical preparations and substances for the treatment of active systemic juvenile idiopathic arthritis; pharmaceutical preparations and substances for use in endocrinology; pharmaceutical preparations and substances for use in the treatment of respiratory conditions; pharmaceutical preparations and substances for use in the treatment of coronavirus disease;; pharmaceutical preparations and substances for use in the treatment of cytokine release syndrome; all the above being for human use.
Pharmaceutical preparations and substances for the treatment of osteop...
Theramex HQ UK Limited
2430180 · 23 Feb 2024
005
Class 005
Pharmaceutical Products
Pharmaceutical preparations and substances for the treatment of osteoporosis; pharmaceutical preparations and substances for the alleviation of osteoporosis-related symptoms; pharmaceutical preparations and substances for the treatment of cartilage disorders; pharmaceutical preparations and substances for the treatment of bone disorders; pharmaceutical preparations and substances for the treatment of bone loss; pharmaceutical preparations and substances for the alleviation of bone-loss related symptoms; pharmaceutical preparations and substances for use in endocrinology; pharmaceutical preparations and substances for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures; pharmaceutical preparations and substances for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures; pharmaceutical preparations and substances for the treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture; pharmaceutical preparations for the treatment of menopause; pharmaceutical preparations and substances for the alleviation of menopause-related symptoms; pharmaceutical preparations and substances for use in relation to women’s health; pharmaceutical preparations and substances for use in rheumatology; pharmaceutical preparations and substances for the treatment of arthritis; pharmaceutical preparations and substances for the treatment of rheumatoid arthritis; pharmaceutical preparations and substances for the treatment of juvenile idiopathic polyarthritis; pharmaceutical preparations and substances for the treatment of active systemic juvenile idiopathic arthritis; pharmaceutical preparations and substances for use in endocrinology; pharmaceutical preparations and substances for use in the treatment of respiratory conditions; pharmaceutical preparations and substances for use in the treatment of coronavirus disease;; pharmaceutical preparations and substances for use in the treatment of cytokine release syndrome; all the above being for human use.
Pharmaceutical preparations and substances for the treatment of osteop...
